BRAF and non-small cell lung carcinoma: The efficacy of ICIs in patients with BRAF-mutant NSCLC is not well established, as some smaller studies indicate limited effectiveness when used as a monotherapy in this subgroup, with findings that have stirred some controversy (24, 25).